Wei L He

US Patent:

8309299, Nov 13, 2012

Filed:

May 2, 2011

Appl. No.:

13/098527

Inventors:

John Frederick Boylan - Bedminster NJ, US
Wei He - New York NY, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C12Q 1/68
G01N 33/53
G01N 33/68

US Classification:

435 4, 435 61, 435 617, 435 71

Abstract:

The present invention relates to a method for determining a subject's resistance to treatment with 2,2-dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide by measuring the levels a biomarker or biomarkers present in a biological sample obtained from the subject, the biomarker being IL6 and/or IL8. The present invention also relates to a combination therapy for a patient suffering from a proliferative disorder comprising administering to the patient 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide and an anti-IL6 and/or an anti-IL8 agent.

US Patent:

8440652, May 14, 2013

Filed:

Mar 2, 2012

Appl. No.:

13/410407

Inventors:

David John Augeri - Princeton NJ, US
Jeffrey Thomas Bagdanoff - Martinez CA, US
Simon David Peter Baugh - Ringoes NJ, US
Marianne Carlsen - Yardley PA, US
Kenneth Gordon Carson - Princeton NJ, US
John Anthony Gilleran - Bridgewater NJ, US
Wei He - Lawrenceville NJ, US
Tamas Oravecz - The Woodlands TX, US
Leonard Sung - Hopewell NJ, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07D 401/14
C07D 495/04
A61K 31/4418
A61K 31/444

US Classification:

51421105, 514309, 514352, 514334, 51425505, 514333, 514221, 514301, 51421207, 544405, 546141, 546309, 546257, 546256, 546114, 540504, 540490

Abstract:

Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders. Particular compounds are of the formula:.

US Patent:

8560476, Oct 15, 2013

Filed:

Jan 24, 2008

Appl. No.:

12/019347

Inventors:

Roger N. Anderson - New York NY, US
Albert Boulanger - New York NY, US
Wei He - Tappan NY, US
Ulisses Mello - Yorktown Heights NY, US
Liqing Xu - Tenafly NJ, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G06F 17/00
G06N 5/00
G06G 7/48

US Classification:

706 45, 703 10

Abstract:

A computer-aided lean management (CALM) controller system recommends actions and manages production in an oil and gas reservoir/field as its properties and conditions change with time. The reservoir/field is characterized and represented as an electronic-field (“e-field”). A plurality of system applications describe dynamic and static e-field properties and conditions. The application workflows are integrated and combined in a feedback loop between actions taken in the field and metrics that score the success or failure of those actions. A controller/optimizer operates on the combination of the application workflows to compute production strategies and actions. The controller/optimizer is configured to generate a best action sequence for production, which is economically “always-in-the-money. ”.

US Patent:

20110112176, May 12, 2011

Filed:

Nov 5, 2010

Appl. No.:

12/940083

Inventors:

John Frederick Boylan - Bedminster NJ, US
Birgit Bramlage - Kulmbach, DE
Wei He - New York NY, US
Markus Hossbach - Kulmbach, DE
Ingo Roehl - Memmelsdorf, DE

International Classification:

A61K 31/713
C07H 21/02
C12N 15/63
C12N 5/10
A61P 35/00

US Classification:

514 44 R, 536 231, 4353201, 435365

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a KIF10 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a KIF10 gene using said pharmaceutical composition; and methods for inhibiting the expression of KIF10 in a cell.

US Patent:

20130072543, Mar 21, 2013

Filed:

Jul 5, 2012

Appl. No.:

13/541891

Inventors:

John Frederick Boylan - Bedminster NJ, US
Wei He - Livingston NJ, US

Assignee:

ARROWHEAD RESEARCH CORPORATION - Pasadena CA

International Classification:

A61K 47/22

US Classification:

514 44 A, 977773

Abstract:

The invention relates to compositions containing compounds of formula I:and pharmaceutically acceptable salts thereof, wherein R, R, R, R, and n are defined in the detailed description and claims. In addition, the present invention relates to novel formulations containing compounds of formula I for improved delivery of nucleic acids such as siRNA to the cytoplasm of target cells. In particular embodiments these formulations comprise compounds of formula I, phospholipids, cholesterol, and pegylated lipids. The present invention also relates to methods of manufacturing and using such compounds and compositions.

US Patent:

20130079383, Mar 28, 2013

Filed:

Jul 5, 2012

Appl. No.:

13/541903

Inventors:

John Frederick BOYLAN - Bedminster NJ, US
Robert A. GOODNOW - Gillette NJ, US
Wei HE - Livingston NJ, US
Tai-An LIN - Pequannock NJ, US
Achyutharao SIDDURI - Livingston NJ, US

Assignee:

ARROWHEAD RESEARCH CORPORATION - Pasadena CA

International Classification:

C07C 237/40
A61K 47/18

US Classification:

514 44 A, 562448

Abstract:

The invention relates to the compounds of formula I:and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.

US Patent:

20130310358, Nov 21, 2013

Filed:

Jul 25, 2013

Appl. No.:

13/950952

Inventors:

- Beerse, BE
Haiyan Bian - Princeton NJ, US
Peter J. Connolly - New Providence NJ, US
Giles Bignan - Bridgewater NJ, US
Chaozhong Cai - North Wales PA, US
Scott L. Dax - Landenberg PA, US
Bart L. DeCorte - Southampton PA, US
Shu-Chen Lin - Doylestown PA, US
Li Liu - Germantown MD, US
Mark J. Macielag - Gwynedd Valley PA, US
Philip M. Pitis - North Wales PA, US
Yue-Mei Zhang - Belle Mead NJ, US
Bin Zhu - Newtown PA, US
Wei He - Audubon PA, US

Assignee:

Janssen Pharmaceutica, NV - Beerse

International Classification:

C07D 239/47
C07D 413/14
C07D 403/14
C07D 403/04
C07D 401/04
C07D 409/14
C07D 405/14
C07D 417/14
C07D 401/14
C07D 401/12

US Classification:

5142102, 514269, 514274, 51425218, 514249, 5142358, 51425505, 51425214, 514218

Abstract:

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:wherein R, R, R, and L, A, and Rare defined herein.

US Patent:

53114841, May 10, 1994

Filed:

Jul 26, 1991

Appl. No.:

7/736682

Inventors:

Roger N. Anderson - New York NY
Wei He - Closter NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01V 100
G01V 128

US Classification:

367 38

Abstract:

In the exploration for petroleum or natural gas, drilling targets are identified by locating local maxima of horizontal gradient in the top-of-geopressure surface of a region of exploration. The probability of finding hydrocarbon deposits is significantly improved where the drilling targets are local maxima of the horizontal gradient in the top-of-geopressure surface which coincide with local maxima of subsurface heat flow in the region of exploration, particularly where the local maxima in the horizontal gradient of the top-of-geopressured surface is concentrated across major fault offsets and are parallel to the predominant strike directions of the faults. The top-of-geopressure surface may be remotely sensed by performing complex trace analysis on reflection seismic traces gathered for the region of exploration to derive corresponding reflection strength attribute traces. The corresponding reflection strength traces are first smoothed and then subject to further complex trace analysis to derive the envelope amplitudes of the smoothed reflection strength traces, which are referred to as second reflection strength traces. The second reflection strength traces are then analyzed to locate an uppermost distinct subsurface boundary between high and low amplitude components thereof.